Summit's ivonescimab shows 70.8% ORR in Phase II colorectal cancer trial

Summit Therapeutics presented Phase II data for ivonescimab combined with chemotherapy in first-line metastatic colorectal cancer, achieving a 70.8% objective response rate with manageable safety profile. The results support continued clinical development of the bispecific antibody candidate and compare favorably to historical benchmarks for standard-of-care treatments.